Displaying drugs 26 - 50 of 403 in total
| Name | Weight | Structure | Desription | Categories |
|---|---|---|---|---|
| Anakinra | 17257.6 C759H1186N208O232S10 |  | A recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis, neonatal-onset multisystem inflammatory disease and deficiency of interleukin-1 receptor antagonist (DIRA). | Interleukin Inhibitors |
| Ancestim | 18540.0 C1662H2650N422O512S18 |  | A human stem cell factor used in combination with filgrastim during autologous peripheral blood progenitor cell (PBPC) transplantation to increase PBPC mobilization for improved collection. | Colony-Stimulating Factors |
| Andexanet alfa | Not Available |  | A recombinant Factor Xa used to reverse anticoagulation caused by rivaroxaban and apixaban. | Antidotes |
| Angiotensin II | Not Available | | A peptide hormone of the RAAS system used to raise blood pressure in septic or other forms of shock. | Angiotensin II, antagonists & inhibitors / Angiotensins / Autacoids / Neuropeptides / Oligopeptides / Peptide Hormones / Vasoconstrictor Agents |
| Anifrolumab | 148000.0 | | A monoclonal antibody that inhibits type 1 interferon receptors, indicated in the treatment of moderate to severe systemic lupus erythematosus. | Selective Immunosuppressants |
| Anistreplase | 59042.3 C2569H3928N746O781S40 |  | A form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli. | Enzymes |
| Anthrax immune globulin human | Not Available | | An immunizing agent used for the treatment of inhalational anthrax in adult and pediatric patients in combination with antibacterial agents. | Amino Acids, Peptides, and Proteins / Blood Proteins / Human Immunoglobulin / Immunoglobulins / Proteins / Serum / Serum Globulins / Vaccines |
| Anti-inhibitor coagulant complex | Not Available | | A medication used to control bleeding episodes and prevent bleeding episodes in hemophilia A and B. | Blood Coagulation Factors |
| Antihemophilic factor (recombinant), PEGylated | 284.0 | | For the management of hemophilia A (congenital factor VIII deficiency) [FDA label], . This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older)... | Recombinant Proteins |
| Antihemophilic factor human | 480000.0 |  | A Factor VIII replacement therapy used to treat hemophilia A. | Blood Coagulation Factors |
| Antihemophilic factor, human recombinant | 264725.5 C11794H18314N3220O3553S83 |  | A form of recombinant coagulation Factor VIII used to treat hemophilia A, von Willebrand disease, and Factor XIII deficiency. | Blood Coagulation Factors |
| Antilymphocyte immunoglobulin (horse) | Not Available | | A primarily IgG immune globulin used to manage allograft rejection in renal transplant patients. | Selective Immunosuppressants |
| Antithrombin Alfa | Not Available | | A recombinant antithrombin used to treat peri-operative and peripartum thromboembolic events in hereditary antithrombin deficiency. | Recombinant Antithrombin |
| Antithrombin III human | Not Available | | An alpha-2-glycoprotein used to prevent thromboembolisms in patients with hereditary antithrombin III deficiency. | Alpha-Globulins / Antithrombin III / Antithrombin III, agonists / Antithrombin Proteins / Blood Coagulation Factor Inhibitors |
| Antithymocyte immunoglobulin (rabbit) | Not Annotated |  | A purified form of rabbit anti-thymocyte antibodies used for immunosuppression in patients receiving kidney transplants. | Selective Immunosuppressants |
| Apadamtase alfa | Not Available | | A recombinant human ADAMTS13 for enzyme replacement therapy in patients with congenital thrombotic thrombocytopenic purpura. | Recombinant Proteins |
| Aprotinin | 6511.439 C284H432N84O79S7 |  | A serine protease inhibitor used to reduce the risk for perioperative blood loss and the need for blood transfusion in high-risk patients during cardiopulmonary bypass for coronary artery bypass graft surgery. | Proteinase Inhibitors |
| Asfotase alfa | 180000.0 C7108H11008N1968O2206S56 |  | An enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP). | Enzyme Replacement Therapy / Enzymes / Tissue-nonspecific Alkaline Phosphatase |
| Asparaginase Erwinia chrysanthemi | 140000.0 C1546H2510N432O476S9 |  | An asparagine-specific enzyme used as part of a chemotherapeutic regimen to treat patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. | Amidohydrolases / Antineoplastic Agents / Asparagine-specific Enzyme |
| Asparaginase Escherichia coli | C1377H2208N382O442S17 |  | An asparaginase enzyme from E. coli used as part of treatment regimens for acute lymphoblastic leukemias. | Amidohydrolases / Asparagine-specific Enzyme |
| Atezolizumab | 145000.0 | | A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. | Antibodies, Monoclonal / PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| Atoltivimab | 145097.54 C6448H9954N1726O2002S44 | | Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. | Antiviral Agents |
| Avalglucosidase alfa | 124000.0 C4490H6818N1197O1299S32 | | A lysosomal glycogen-specific enzyme that is used to treat patients one year of age and older with late-onset Pompe disease, or lysosomal acid alpha-glucosidase (GAA) deficiency. | Enzymes |
| Avelumab | 147000.0 C6374H9898N1694O2010S44 | | An anti-PD-L1 monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma. | Antibodies, Monoclonal / PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| Bamlanivimab | 146000.0 C6498H10068N1732O2032S46 | | A neutralizing human IgG1κ monoclonal antibody against the SARS-CoV-2 spike (S) protein for use in patients aged 12 and over at high risk of developing severe COVID-19. | Antiviral Agents |
Displaying drugs 26 - 50 of 403 in total